The in vitro activity of leridistim was characterized for cell proliferation, generation of colony-forming units (CFU) and differentiation of CD34 + cells. In AML-193.1.3 cells, leridistim exhibited a significant increase in potency compared to rhG-CSF, SC-65303 (an IL-3 receptor agonist) or an equimolar combination of rhG-CSF and SC-65303. CFU-GM assays demonstrated that at 50% of the maximum response, the relative potency of leridistim was 12-fold greater than the combination of rhG-CSF and rhIL-3 and 44-fold more potent than rhG-CSF alone. In multi-lineage CFU assays, a combination of erythropoietin (rhEPO) and leridistim resulted in greater numbers of BFU-E, CFU-GEMM and CFU-Mk than rhEPO alone. ). These results demonstrate that leridistim is a more potent stimulator of hematopoietic proliferation and differentiation than the single receptor agonists (rhG-CSF and SC-65303) either alone or combined. These unique attributes suggest that leridistim may enhance hematopoietic reconstitution following myelosuppressive chemotherapy.
Introduction
Currently, recombinant G-CSF is the standard of care for neutrophil recovery following chemotherapy, as well as for the mobilization of progenitor cells for transplant. [1] [2] [3] [4] However, despite significant reduction in the duration of severe neutropenia, rhG-CSF has limited effect on the depth of the neutrophil nadir. 5 Additionally, rhG-CSF has not been effective in preventing or treating chemotherapy-induced thrombocytopenia. [6] [7] [8] Combination therapy with multiple growth factors greatly enhances the production or mobilization of hematopoietic progenitor cells of the granulocyte and macrophage lineages. [9] [10] [11] [12] [13] [14] Similarly, production of cells of the erythroid and megakaryocyte lineages can be enhanced by appropriate growth factor combination therapy, most notably in the presence of interleukin (IL)-3 receptor agonists. [15] [16] [17] [18] [19] IL-3 is an early-acting multilineage hematopoietic growth factor which stimulates the production of neutrophils, monocytes, eosinophils, erythroid cells, multipotent progenitors and megakaryocytes. [20] [21] [22] IL-3 acts synergistically with specific differentiation factors, such as G-CSF, GM-CSF, thrombopoietin and IL-6. 23 The expansion of hematopoietic progenitor cells and differentiation of committed precursors of various lineages can be accomplished by optimization of ex vivo culture systems with a mixture of 'early-acting' and lineage-specific cytokines. 14, 24 Employment of a combinatorial mutagenesis strategy of the human IL-3 molecule resulted in several analogs exhibiting increased proliferative activity and hematopoietic potency relative to native IL-3. [25] [26] [27] Recently, it has been shown that the addition of daniplestim, one of these potent IL-3 receptor agonists, to ex vivo CD34 + cell cultures resulted in a greater increase in granulopoietic post-progenitor cells, suggesting that IL-3 receptor agonists can synergize with other lineage-specific cytokines in promoting expansion and differentiation of CD34 + cells. 28 Studies conducted in non-human primate models have demonstrated that daniplestim can potentiate the in vivo effects of rhG-CSF on mobilization of progenitor cells and neutrophil restoration, and can also prevent thrombocytopenia. 27, 29, 30 Clinically, the combination of daniplestim with rhG-CSF has been shown to improve mobilization of progenitor cells in cancer patients. 31 These observations provided the rationale for the development of a family of engineered proteins termed myelopoietins (MPOs), which result from the combination of an early-acting multilineage factor (rhIL-3) with a lineage-specific factor (rhG-CSF) within a single molecule thereby engendering it with unique biological properties. 32 A prototype MPO (SC-68420) was created containing the IL-3 receptor agonist moiety present in daniplestim linked to rhG-CSF that was shown to enhance the proliferation and suppress apoptosis of responsive cell lines. [33] [34] [35] [36] Treatment with this prototype MPO in a non-human primate model of radiation-induced myelosuppression resulted in a dramatic, dose-related improvement in the neutrophil and platelet nadir, a reduction in the duration of neutropenia and thrombocytopenia and a reduced time to recovery of neutrophil and platelet values. 37, 38 Another IL-3 agonist, SC-65303, consisted of an N-and C-terminal truncated IL-3 receptor agonist containing a single E50D substitution (15-125, 50D) , and showed two-to four-fold better potency than rhIL-3 in IL-3 receptor-positive cell lines. Leridistim is a specific MPO consisting of the SC-65303 sequence at the N terminus linked to a G-CSF receptor agonist (G-CSF, Ser 17 ) with a 35 amino acid sequence based on the IgG 2b hinge region. 32 In this paper, we report in vitro proliferation activity of leridistim in BaF3/G-CSFR (G-CSF receptor positive), TF-1 (IL-3 receptor positive) and AML-193.1.3 (IL-3 and G-CSF receptor positive) cell lines. The biological activity of leridistim in bone marrow CD34
+ CFU assays demonstrated that leridistim was more potent than either rhG-CSF or SC-65303 alone or in equimolar combination. In addition, leridistim resulted in greater expansion of granulocytic and monocytic precursor cells in ex vivo liquid culture assays than did the cytokine combination. Finally, leridistim was more potent in stimulating megakaryocytic precursors than rhG-CSF alone. The unique hematopoietic activity profile of leridistim suggests that it could offer a promising alternative for alleviation of chemotherapy-induced neutropenia and thrombocytopenia.
Materials and methods

Growth factors
Leridistim, SC-65303, rhIL-3 and c-mpl ligand were produced as described previously. 26, 27, 32 Recombinant G-CSF (Neupogen) and rhEPO (Procrit) were obtained from Amgen (Thousand Oaks, CA, USA).
Cell proliferation assays
G-CSFR-dependent proliferative activity was measured using transfected BaF3/G-CSFR cells as described previously.
32,39 IL-3R-dependent proliferative activity was measured using TF-1 cells while AML-193.1.3 cells were utilized to measure dual IL-3R and G-CSFR proliferative activity, as previously described. 27 
Isolation of CD34 + cells from peripheral blood and bone marrow
Aspirates of fresh bone marrow (BM) were obtained from healthy donors through collaboration with St Louis University Health Sciences Center (St Louis, MO, USA), following informed consent. Mononuclear cell fractions were recovered following density-gradient centrifugation (20 min, 800 g) with Ficoll-Hypaque (density = 1.077 0.001 g/ml) (Lymphoprep, Nycomed Pharma, Oslo, Norway). CD34
+ cells were subsequently isolated by positive selection using the Isolex 50 stem cell reagent kit (Nexell Therapeutics, Irvine, CA, USA), according to the manufacturer's directions. Peripheral blood mononuclear cells (PBMC) were obtained from healthy donors mobilized with 10 g/kg/day rhG-CSF for 4 days. CD34
+ cells were purified from these mobilized cells using the Isolex 300i Magnetic Cell Separation System at Nexell Therapeutics. These procedures yielded an enriched cellular product where Ͼ90% of the cells expressed the CD34 surface antigen as determined by cell surface phenotyping with a fluorescein isothiocyanate (FITC)-conjugated CD34 antibody (Becton Dickinson, San Jose, CA, USA). Bone marrow CD34
+ cells were cryopreserved in X-VIVO 10 (BioWhittaker, Gaithersburg, MD, USA) containing 10% DMSO and 12.5% HSA at 1 × 10 6 cells/ml.
Granulocyte/macrophage colony-forming unit assay
Freshly isolated or cryopreserved BM CD34 + cells were established in triplicate in 35-mm tissue culture dishes containing 5 × 10 3 cells/dish and serial dilutions of leridistim, rhG-CSF, SC-65303, rhIL-3, or rhG-CSF with either SC-65303 or rhIL-3. In the combinations, the concentrations of the individual receptor agonists were equimolar to the concentration of leridistim. The culture medium consisted of MethoCult H4230; (StemCell Technologies, Vancouver, BC, Canada) containing 0.9% methylcellulose in IMDM, 30% FBS, 1% BSA, 100 M 2-mercaptoethanol and 2 mM L-glutamine. Cultures were incubated at 37°C, 5% CO 2 in humidified air for 11-12 days.
Leukemia CFU-GM colonies (у50 cells/colony) were enumerated using inverted phase microscopy.
Multiple-lineage colony-forming unit assays (CD34
+ or mononuclear cells)
Bone marrow CD34
+ cells were cultured as described above at 1.5 × 10 3 cells/well with serial dilutions of either leridistim, SC-65303, rhG-CSF, or an equimolar combination of rhG-CSF and SC-65303. The culture medium consisted of Methocult H4330 (StemCell Technologies), which in addition to the components listed for the CFU-GM assay, contained 3 units/ml recombinant erythropoietin (rhEPO). Alternatively, similar assays were set up with BM mononuclear cell preparations without further purification of CD34 + cells. Freshly isolated mononuclear cells were cultured at 1 × 10 5 cells/well in MethoCult H4230 and rhEPO was titrated with equimolar combinations of the other growth factors. Cultures were incubated at 37°C, 5% CO 2 in humidified air for 14 days. CFU-GM (у50 granulocyte or macrophage cells/colony), BFU-E (Ͼ100 cells in three or more erythroblast clusters, or Ͼ200 cells in a single cluster), CFU-E (8-200 erythroblasts in one to two clusters) and CFU-GEMM colonies were enumerated using inverted phase microscopy.
Megakaryocyte colony-forming unit assay
Bone marrow CD34 + cells were cultured using the Megacult-C slide/chamber system (StemCell Technologies) containing 1.1 mg/ml collagen, 1% BSA, 10 g/ml bovine pancreatic insulin, 200 g/ml human transferrin, 100 M 2-mercaptoethanol and 2 mM L-glutamine in IMDM according to the manufacturer's instructions. Cells were cultured in duplicate double chamber slides containing 5 × 10 3 cells/chamber, and the following treatments: control cocktail (rhTPO at 50 ng/ml, rhIL-6 at 10 ng/ml, rhIL-3 at 10 ng/ml), leridistim (200 ng/ml), rhG-CSF (100 ng/ml), SC-65303 (100 ng/ml), or c-mpl ligand (100 ng/ml). Cultures were incubated at 37°C, 5% CO 2 in humidified air for 11-12 days. Slides were dehydrated with filter cards, fixed in a 1:3 methanol:acetone solution for 20 min, and allowed to air dry. Three chambers from each treatment were stained with a primary antibody to glycoprotein CD41, and amplified using a biotinylated antibody-alkaline phosphatase. Cells positive for CD41 appeared pink, and the nuclei of all lineages appeared blue following a counter-stain with Evans Blue. The fourth chamber was stained with an isotype control antibody. Cultures were scored for small CFUMk (3-20 cells/colony), medium CFU-Mk (21-49 cells/colony), large CFU-Mk (у50 cells/colony), mixed CFUMk/GM colonies, and non-Mk (CFU-GM) colonies.
Ex vivo cell culture
Peripheral blood progenitor cells (PBPC) or bone marrow CD34 + cells were cultured in X-VIVO 10 supplemented with 1% human serum albumin (HSA; Immuno-US, Rochester, MI, USA). Cells were seeded at 1 × 10 4 cells per ml into 75-cm 2 tissue culture flasks (Costar, Cambridge, MA, USA) containing either 100 ng/ml leridistim, 100 ng/ml rhG-CSF, 100 ng/ml SC-65303, or both rhG-CSF and SC-65303, each at 100 ng/ml. 4 cells were incubated with 25 l mouse IgG 2a , kappa (Sigma) for 30 min followed by incubation with 25 l of a predetermined optimum antibody concentration for 30 min on ice. After incubation with antibodies the cells were washed twice and resuspended in 75 l of PBS and 75 l of FACS Fixative containing 20% formaldehyde (Tousimis Research, Rockville, MD, USA). Data were analyzed using WinList for Win 32 (Verity Software House, Topsham, ME, USA). Additionally, bone marrow cells were stained with CD15FITC/CD11bPE after a 12-day incubation with leridistim and sorted by FACSVantageSE (Becton Dickinson). The cells were centrifuged on to glass slides by cytospin (500 r.p.m., 5 min) and stained with Wright-Giemsa for qualitative morphological assessment using light microscopy of the neutrophil populations.
Statistical analysis
The variables for each compound were measured either in different experiments or different donors. To increase the sensitivity of the analysis, experiments or donors were used as blocking factors in the statistical analysis. The analysis was conducted on the raw data values if the assumptions of normality and equality of variance were both shown to be satisfied. If not, then either a log or a rank transformation was used. Randomized block analysis of variance was used for the analysis on raw or log transformed data. For rank transformed data, first the data were ranked within each donor and then a one-way analysis of variance was performed. In either case, the least significant differences means comparison procedure was used for the planned comparisons between compounds.
Results
Structure and sequence of leridistim
Myelopoietins (MPO) are a family of multifunctional hematopoietic growth factors that activate the human IL-3 and G-CSF receptors. Leridistim, is a specific MPO containing an N-and C-terminal truncated IL-3 receptor agonist (SC-65303) with a glutamic acid to aspartic acid substitution at residue 50 (15-125, 50D) and a G-CSF analog (G-CSF Ser 17 ), linked together with the hinge region of IgG 2b ( Figure 1 ). This unique combination of receptor agonist moieties has engendered this molecule with the unique biological properties described below.
Leridistim induces proliferation of cells expressing IL-3 and G-CSF receptors
The ability of leridistim to promote receptor-dependent proliferation was measured using three different cell types including transformed BaF3 cells engineered to express human G-CSF receptors (ie BaF3/G-CSFR), human TF-1 cells which express IL-3 ␣ and ␤ c receptors and human AML-193.1.3 cells which express both IL-3 ␣ and ␤ c receptors as well as G-CSF receptor. 26, 27, 40 Leridistim, rhG-CSF, or the equimolar combination of rhG-CSF and SC-65303 promoted dose-dependent proliferation of the BaF3/G-CSFR cells (Table 1) and relative potency determination (see Table 1 legend) revealed that leridistim was moderately, but significantly, more potent than rhG-CSF in this assay. Incubation of TF-1 cells with leridistim, SC-65303, rhIL-3 or rhG-CSF and SC-65303 also promoted dose-dependent proliferation, and relative potency determination suggested that leridistim is less potent than rhIL-3 whereas SC-65303 and the combination of rhG-CSF plus SC-65303 were more potent than rhIL-3 in this assay. Incubation of AML-193.1.3 cells with leridistim, rhG-CSF, SC-65303, rhG-CSF plus SC-65303 or rhIL-3 promoted dose-dependent proliferation and it is important to note that maximum proliferation with rhG-CSF was four-to eight-fold less than that obtained with other growth factors. Comparison of the relative potency values indicates that both leridistim and the combination of rhG-CSF and SC-65303 were more potent than rhIL-3. The cell proliferation data in these three cell lines suggest that leridistim is more potent in inducing proliferation of cells that express both IL-3R␣␤ c and G-CSFR.
Figure 1
Amino acid sequence of leridistim. Leridistim is a specific MPO expressed in E. coli using recombinant DNA technology. It contains an N-and C-terminal truncated IL-3 receptor agonist (SC-65303) with a glutamic acid to aspartic acid substitution at residue 50 (15-125, 50D) and a G-CSF analog (G-CSF Ser 17 ), linked together with the hinge region of IgG 2b (in bold type). 
Leridistim is a potent stimulator of CFU-GM
The ability of leridistim to activate primary hematopoietic cells was examined in CFU-GM assays using human bone marrow CD34 + cells from six donors. A representative graph illustrating the production of CFU-GM in response to leridistim, rhG-CSF, SC-65303, rhIL-3, and either SC-65303 or rhIL-3 in combination with rhG-CSF is shown in Figure 2 . The relative response values for each treatment compared to the combination of rhG-CSF and rhIL-3 are compiled in Table 2 . The generation of CFU-GM at saturating concentrations of leridistim was comparable to that of the combinations, and greater than rhG-CSF, SC-65303 or rhIL-3 alone. The mean maximal responses for leridistim and rhG-CSF were 1.03 and 0.68, respectively, relative to the combination of rhG-CSF and rhIL-3, indicating that rhG-CSF alone results in a significantly lower maximal CFU-GM response (P Ͻ 0.001). Interestingly, the relative potency of leridistim at 50% of the maximal CFU-GM response was significantly greater than the other test growth factors, indicating that lower concentrations of leridistim were required to produce equivalent CFU-GM responses (P Ͻ 0.001). In fact, at 50% of the maximum CFU-GM, the relative potency of leridistim was greater than that of rhG-CSF, rhIL-3, rhG-CSF and rhIL-3, or rhG-CSF and SC-65303 (12.52 vs 0.28, 0.20, 1 and 1.2). Taken together, these data demonstrate that leridistim stimulates a greater maximal number of clonogenic progenitor cells (CFU-GM) than rhG-CSF at saturating concentrations. Additionally, leridistim produces more colonies at sub-maximal concentrations than either rhG-CSF alone or the combination of rhG-CSF and rhIL-3 added in equivalent concentrations.
Leridistim stimulates generation of erythroid and multiple lineage colonies
Additional CFU studies were conducted in the presence of a constant level of rhEPO to allow simultaneous evaluation of CFU-GM, erythroid (BFU-E and CFU-E), and multilineage colonies (CFU-GEMM). The mean responses achieved with leridistim, rhG-CSF, SC-65303, and rhG-CSF in combination with Leukemia SC-65303 are shown in Table 3 . Analysis of the multi-lineage growth factor effect on CD34
+ cells revealed little doseresponse effect with saturating rhEPO concentrations, therefore the maximum value for each test growth factor was calculated as the average response across the three highest concentrations (0.01, 0.1 and 1.0 nM) and compared to one another and to the response of rhEPO alone. Leridistim significantly increased the number of BFU-E and CFU-GEMM, but did not enhance numbers of CFU-E colonies over treatment with rhEPO alone. In contrast, the addition of rhG-CSF to rhEPO did not result in increased BFU-E, CFU-E or CFU-GEMM suggesting that rhG-CSF does not have an impact on multi-lineage colony formation. Increases in BFU-E and CFU-GEMM were also observed in the presence of SC-65303 and in the combination of rhG-CSF and SC-65303, indicating that the presence of an IL-3 receptor agonist played a significant role in the generation of BFU-E and CFU-GEMM. Furthermore, generation of CFU-GEMM induced by leridistim was significantly greater than that of either SC-65303 alone or the combination of rhG-CSF and SC-65303, demonstrating again that leridistim was highly potent in stimulating colony formation from early progenitor cells. Generation of CFU-GM colonies exhibited similar maximal responses and an identical order of potency as observed earlier in the absence of rhEPO (ie leridistim Ͼ SC-65303 plus rhG-CSF Ͼ rhG-CSF Ͼ SC-65303), suggesting that the erythroid and multi-lineage colonies in the presence of EPO were not generated at the expense of CFU-GM (data not shown).
Experiments employing unfractionated mononuclear cell preparations, rather than enriched CD34 + cells, were utilized to confirm the observations from CD34 + cells. This allowed inclusion of the most primitive multipotent stem cells as well as mature erythroid progenitors, which may have been excluded from the purified CD34 + cell preparation. These experiments also differed in that rhEPO was titrated at equivalent concentrations with each growth factor. Titration of rhEPO resulted in a dose-related production of erythroid and multilineage colonies by the various growth factors or growth factor mixtures ( Figure 3) . No significant differences were observed among the treatments, at dose levels of 0.01 and 0.1 nM, in the production of CFU-E (Figure 3a) . At 1.0 nM the mean
Leukemia
Figure 2
CFU-GM response of leridistim. CD34 + cells were isolated from human bone marrow and cultured in methylcellulose for 11-12 days. Hematopoietic colonies (у50 cells/colony) were counted using an inverted phase microscope. The graph represents data from six donors s.e.m. The concentration of the individual receptor agonists in the combination curves are equimolar and equivalent to the concentration of leridistim at each data point. (᭺) rhIL-3, (̅) SC-65303, (᭺) rhG-CSF, () rhG-CSF+rhIL-3, (̆) rhG-CSF plus SC-65303, (í) leridistim.
CFU-E responses for the combinations of rhEPO and leridistim or rhEPO and SC-65303 were not different from each other, but were significantly higher than the responses for rhEPO alone or rhEPO and rhG-CSF, which were not different from each other.
As shown in Figure 3b , significant differences were observed in BFU-E colony numbers among the compounds at all three concentrations. The average responses for treatment with the combinations of rhEPO with leridistim, rhEPO with rhG-CSF and SC-65303, and rhEPO with SC-65303 at 1.0 nM were not significantly different from each other, but were significantly greater than the response for rhEPO alone and the combination of rhEPO and rhG-CSF.
The various growth factor treatments also produced different numbers of CFU-GEMM (Figure 3c ) at all three concentrations, although the frequency of colonies produced from these early progenitor cells was very low. At 1.0 nM, the mean CFU-GEMM for the combinations of rhEPO and leridistim, rhG-CSF; (P Ͻ 0.001, randomized complete block analysis of variance, two-tailed). CFU activity was measured after 14 days of culture as described in Materials and methods. Data depict mean values for each test growth factor calculated as the average response across the highest three levels of drug (0.01-1.0 nM) and compared to one another and to the response with rhEPO alone (3 U/ml). Donor-to-donor variability was normalized and accounted for in the statistical analysis (therefore, no error values are shown). Assays were performed with CD34 + cells taken from four donors. Compounds significantly different to a rhEPO alone; different to b leridistim; (P Ͻ 0.0001, randomized complete block analysis of variance, two-tailed).
rhEPO and rhG-CSF and SC-65303 or rhEPO and SC-65303 were not significantly different from each other, but were significantly different from the other two treatment groups, where no CFU-GEMM colonies were observed. Thus, the enhanced effect of leridistim on CD34 + , over treatment with all three growth factors, was not apparent in the unselected population. The frequency of GEMM cells in this population may be too low to observe this effect, since the maximum number observed among the treatments was less than 0.01%. Therefore, the selection process enriches for progenitor cells that are responsive to simultaneous growth factor stimulation.
Figure 3
Multilineage colony formation stimulated by leridistim in culture. Bone marrow mononuclear cells were isolated and cultured in the presence of rhEPO and the indicated cytokines for 14 days. (a) CFU-E colonies containing 8-200 erythroblasts/colony in one to two clusters. (b) BFU-E colonies containing either Ͼ100 erythroblasts/colony in three or more clusters, or Ͼ200 erythroblasts in a single cluster. (c) CFU-GEMM containing cells from the erythroid and at least one other lineage. Data represent the mean of five different donors ± s.e.m. (donor variability is accounted for in the statistical analysis). The concentration of the individual receptor agonists in the rhG-CSF plus SC-65303 combination are equimolar and equivalent to the concentration of leridistim at each data point. A parametric analysis on the colony counts was performed for CFU-E and BFU-E, and a nonparametric analysis was performed on the ranked data for CFU-GEMM. Compound responses were compared within each concentration. *Values significantly different than both rhEPO alone and rhEPO + rhG-CSF (randomized complete block analysis of variance, two-tailed, P Ͻ 0.05).
Leukemia
Leridistim stimulates development of megakaryocyte colonies
The use of the collagen gel matrix in a CFU assay permits accurate delineation of megakaryocytic colonies. [41] [42] [43] In this megakaryocyte-specific assay, a saturating concentration of leridistim yielded similar numbers of total CFU-Mk colonies as compared with colonies formed in the presence of saturating c-mpl ligand, SC-65303, or the control cocktail (rhTPO, rhIL-6, and rhIL-3) (Figure 4) . Treatment with leridistim yielded a greater number of small CFU-Mk colonies (34 ± 7 vs 21 ± 2), similar numbers of medium colonies (10 ± 5 vs 12 ± 5) but fewer large colonies (0.8 ± 0.5 vs 7 ± 2). Stimulation of CFU-Mk by leridistim was not significantly different than cmpl ligand alone for any of the CFU-Mk colony sizes. Although rhG-CSF did not stimulate the production of CFUMk, the number of CFU-GM colonies generated by rhG-CSF was comparable to stimulation by leridistim. These results suggest that leridistim is as effective as c-mpl ligand in stimulation of megakaryocyte progenitors, and predicts that rhG-CSF may not share this CFU-Mk potential. In fact, rhesus monkeys treated with a prototype MPO showed improvement of all platelet-related parameters in comparison to animals treated with rhG-CSF. 29 
Leridistim expands CD34 + cells ex vivo
The ability of leridistim to promote proliferation and differentiation of committed precursors was examined in ex vivo liquid culture assays. CD34 + cells from rhG-CSF-mobilized peripheral blood (PBMC) and from the bone marrow of normal donors were incubated for up to 12 days with leridistim, rhG-CSF, SC-65303, or the combination of rhG-CSF and SC-65303. Viable cells were evaluated on days 5 and 12. On day 12, there was a 148-fold increase in the number of cells initially plated in PBPC-derived cultures in the presence of leridistim and a 46-fold increase in cells incubated in the presence of SC-65303. Culture with rhG-CSF alone did not lead to increased cell number, rather the cell number declined to 0.6-fold of the initial cell number. In similar experiments, culturing of bone marrow CD34
+ cells with leridistim resulted in a 714-fold increase in cell number at day 12, while SC-65303 promoted a 21-fold increase and the combination of rhG-CSF
Figure 4
CFU-Mk response of leridistim. CD34 + cells were isolated from human bone marrow and cultured with the indicated cytokines, using the Megacult-C slide chamber system for 11-12 days. The slides were dehydrated, fixed, and stained for CD41 antigen as a marker for megakaryocytes. Cultures were scored for small CFU-Mk and SC-65303 promoted a 99-fold cell number increase. When bone marrow CD34
+ cells were cultured with rhG-CSF, expansion was only 1.7-fold. + ). 44 On day 5 of ex vivo culture using peripheral blood CD34 + cells, the progenitor cell population (CD34 + /CD15 − /CD11b − ) comprised the greatest number of cells for each culture condition (Table 4A ). Cultures treated with leridistim, SC-65303, or rhG-CSF and SC-65303 in combination contained monocyte/macrophage precursors whereas there were much lower levels of these cells present in the rhG-CSF cultures. The number of immature neutrophils on day 5 was found to be two-to three-fold greater in the leridistim and the rhG-CSF and SC-65303 combination cultures than in the SC-65303 cultures. More profound differences were observed when leridistim or the rhG-CSF and SC-65303 combination cultures were compared with rhG-CSF cultures (56-and 58-fold greater, respectively). On day 5, greater numbers of mature neutrophils were observed in the leridistim cultures than in cultures with other cytokines. Similar data were obtained for the effect of leridistim on 5 day culture of bone marrowderived cells (Table 4B ). These data suggest that on day 5, leridistim treatment of CD34 + cells from PBPC and BM results in expansion of cells with immature and mature neutrophil characteristics.
Leridistim expands granulocytic precursor cells ex vivo
On day 12, dramatic differences were noted in the distribution of granulocytic precursor cells during ex vivo culture of PBPC and BM cells. At day 12, culture of PBPC CD34
+ cells with leridistim promoted expansion of cells displaying the mature neutrophil phenotype; 13-and 22-fold greater expansion than in the cultures treated with the combination of rhG-CSF and SC-65303, or SC-65303, respectively, and 1131-fold greater than with rhG-CSF. Culture with leridistim, SC-65303, or a combination of rhG-CSF and SC-65303 increased the cells displaying the immature neutrophil cell phenotype 409-, 118-and 123-fold, respectively, over that attained with rhG-CSF treatment. Blast cells and monocyte/macrophage precursors were present in the cultures containing leridistim, SC-65303, or the combination of rhG-CSF and SC-65303 at significantly higher levels than within rhG-CSF cultures.
On day 12, BM CD34 + cells cultured with leridistim demonstrated a dramatic increase in mature neutrophils (707-, 204-and 11.5-fold greater expansion compared to that resulting from rhG-CSF, SC-65303, or the combination of rhG-CSF and SC-65303, respectively) ( Table 4B ). Morphological assessment of CD15 + /CD11b + cells sorted by FACSVantage and stained by Wright-Giemsa showed the characteristic segmented lobes of mature neutrophils (data not shown). The monocyte/macrophage precursor cells were present at higher levels in cultures containing both receptor agonists (ie leridistim or rhG-CSF in combination with SC-65303). Blast cells were present at significantly higher levels in the cultures containing leridistim, SC-65303, or the combination of rhG-CSF and SC-65303. These results suggest that by day 12, leridistim treatment of both PBPC and BM cells induces greater expansion of cells with the mature and immature neutrophil phenotype than the other treatments.
Leridistim maintains early progenitor cells during culture Ex vivo culture of PBPC and BM CD34
+ cells with leridistim resulted in a greater increase in precursor cells without depletion of the progenitor pool. Cultures containing leridistim, SC-65303 or rhG-CSF and SC-65303 contained a significantly higher level of the progenitor cell phenotype (CD34
− , CD11b − ) on days 5 and 12 from both PBPC and bone marrow cell sources compared to rhG-CSF treated cultures (Table 4A and B) .
Leridistim expands monocytes and megakaryocytic precursors
Expression of CD14 and CD41 as markers of monocytic and megakaryocytic cell types was also examined in PBPC and BM CD34
+ cultures. Leridistim, SC-65303 or the combination of rhG-CSF and SC-65303 resulted in increased numbers of cells of the CD41 + cells. These data suggest that in addition to stimulation of granulocytic precursors, leriLeukemia distim also stimulates monocytes and megakaryocytic precursors under tissue culture conditions.
Discussion
In this study, we describe the ability of leridistim, a member of the myelopoietin family, to stimulate the proliferation and differentiation of hematopoietic progenitor cells. Leridistim stimulated proliferation of cell lines that expressed the human IL-3 and G-CSF receptors with greater potency than IL-3 receptor or rhG-CSF receptor agonists, either alone or when combined. Leridistim also stimulated the generation of multilineage colonies from human bone marrow CD34
+ cells beyond that generated by a combination of rhG-CSF and rhIL-3. In addition, leridistim stimulated the differentiation of granulocytic and monocytic precursors to an extent that far exceeded the capacity of rhG-CSF. These data provided the foundation for in vivo studies to examine the efficacy of leridistim in a non-human primate model of hematopoietic reconstitution.
The dual receptor activity of leridistim was observed in proliferation assays using stable cell lines. The enhanced affinity of leridistim for IL-3R compared to rhIL-3 or SC-65303, may result from the simultaneous binding of leridistim to IL-3R and G-CSFR. 33 In BaF3/G-CSFR cells, leridistim and rhG-CSF exhibit similar affinity for the receptor, however, stabilization of the G-CSF moiety of the chimeric molecule may account for the moderate increase in potency exhibited with leridistim. 32 In TF-1 cells, leridistim is less potent than rhIL-3 whereas SC-65303, and the combination of rhG-CSF plus SC-65303 were more potent than rhIL-3. This may be due to a decrease in the association rate with a corresponding decrease in the affinity of leridistim for IL-3R. 33 This enhanced potency with leridistim was also evident in CFU-GM assays. Responses to leridistim in these assays were greater than those achieved by concurrent administration of the individual agonists. 32, 39 The pharmacologic rationale for generating a chimeric molecule with synergistic action was based on the observation that combining an 'early-acting' growth factor such as IL-3 with a lineage-specific growth factor such as G-CSF led to proliferative and differentiative effects. The increased potency of leridistim above the combination of equimolar concentrations of an IL-3 receptor agonist and rhG-CSF raises interesting questions relating to the mechanism of enhancement of the chimeric molecule. An explanation may be that both IL-3 and G-CSF receptors could be activated simultaneously. Receptor binding results using AML-193.1.3 cells and purified receptor proteins were consistent with simultaneous binding of MPO proteins to both G-CSF and IL-3 receptors. Dual receptor binding may stabilize the receptor-ligand complex, thereby increasing the effective concentration of MPO at the receptor sites on the cell, and thus provide a more sustained signal for proliferation and/or differentiation. Indeed, the concept of dual receptor binding was supported in signaling experiments where a greater magnitude and sustained phosphorylation of JAK2 as compared to the combination of IL-3 and rhG-CSF using AML-193.1.3 cells was observed. 33 Based on these observations, we speculate that the ability of leridistim to enhance colony formation with higher potency may result from its unique dual receptor binding and signaling properties. The expression of both IL-3R and G-CSFR on a single cell has also been reported for promyelocytic and myelocytic precursor cells. 24, 45, 46 It is possible that precursor cells expressing dual receptors may be preferentially stimulated by leridistim.
Leukemia
The significant increase in the number of CFU-GEMM colonies by leridistim attests to the stimulation of very primitive hematopoietic progenitors which are frequently presumed to be the self-renewing stem cells. 47 In addition, greater stimulation of BFU-E and CFU-Mk in the presence of leridistim further supports the concept that leridistim acts on an early progenitor cell. These early progenitors have been shown to be intensely sensitive to the priming effects of IL-3 and leridistim may augment this property in some progenitor populations. 19 Whether the progenitor cells or a subset of the cells also contain the G-CSF receptor is unknown.
A point to note is that both leridistim and SC-65303 stimulated equivalent numbers of megakaryocytic colonies even though no c-mpl ligand was present in the medium. In fact, preclinical studies in a rhesus myelosuppression model demonstrated that administration of leridistim (daily or every other day) resulted in reduction in platelet nadir and accelerated recovery compared to autologous serum-treated control animals. 51 These data are in agreement with observations by other investigators that IL-3 also induces megakaryocytic lineage in a cooperative mode with other cytokines such as, IL-6, GM-CSF or EPO. [48] [49] [50] Together, the implications of these observations for in vivo applications are very promising if administration of leridistim were to correspondingly result in the abrogation of chemotherapy-induced thrombocytopenia.
In ex vivo liquid culture assays, leridistim resulted in a robust neutrophil expansion as well as maintenance of CD34 + ) neutrophil phenotypes was observed on day 12 in response to leridistim than with the single agonists or a combination of rhG-CSF and SC-65303. In addition, leridistim continued to support high numbers of uncommitted precursors expressing CD34 antigen until day 12, while cultures with rhG-CSF were almost completely depleted of the CD34 + cells. It may be that inclusion of a highly potent IL-3 receptor agonist (SC-65303) would induce primitive stem cells to self-renew while also inducing proliferation and differentiation along multiple lineages. Another distinctive feature of leridistim as a chimeric molecule with unique receptor binding and activation properties is that it supported maintenance of higher numbers of CD34 + precursor cells on day 12 compared to the combination of rhG-CSF and SC-65303. These observations further support the notion that simultaneous activation of multiple receptors may offer a distinct advantage for self-renewal and maintenance of stem cells. In a transplantation setting, such stem cell renewal and maintenance properties would be highly beneficial for stem cell engraftment.
Differences in the expansion of CD34 + cells from bone marrow vs peripheral blood were also noted. For example, on day 12 leridistim induced greater expansion of total megakaryocytic precursors from BM CD34
+ cells compared to PBPC CD34 + cells. Conversely, the combination of rhG-CSF and SC-65303 induced greater expansion of megakaryocyte precursors (CD41 + /CD14 − ) from PBPC CD34 + cells than from BM CD34 + cells. Some of these differences may relate to the fact that since PBPC CD34 + cells were obtained from rhG-CSFmobilized normal donors they may represent, therefore, a different progenitor pool than BM CD34 + cells. Whether these observations correlate with clinical observations remains to be determined.
In summary, data presented here demonstrate that leridistim is highly potent in stimulating both committed and multipotential progenitors. In contrast to rhG-CSF, leridistim augments granulocytic, monocytic, erythroid and megakaryocytic precursors. In fact, leridistim exhibits a potentiating profile with greater than additive activities of IL-3 receptor agonists and rhG-CSF. These unique attributes of leridistim may enhance its ability for hematopoietic reconstitution following myelosuppressive chemotherapy.
